Citigroup
LTGO

Citigroup’s Latigo Biotherapeutics LTGO Stock Holding History

Citigroup’s Portfolio LTGO Stock Details LTGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.5K Buy
+1,168
New +$24.7K ﹤0.01% 5009

Other funds holding LTGO

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Jacobi Capital Management
Jacobi Capital Management Pittston, Pennsylvania $2.11B AUM 19.6% 1-Year Est. Return

Citigroup's LTGO Position: Q3 2026 in Review

Citigroup opened a new position in Latigo Biotherapeutics (LTGO) in Q3 2026: 1,168 shares worth $19.5K. The stake represents ﹤0.01% of the portfolio and ranks #5009 among its holdings.

6 funds tracked by Wall St. Rank hold LTGO as of Q3 2026.

  • Citigroup held 1,168 shares of Latigo Biotherapeutics worth $19.5K as of Q3 2026.
  • Latigo Biotherapeutics was a new Citigroup position in Q3 2026.
  • Latigo Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5009 holding.
  • 6 funds tracked by Wall St. Rank held Latigo Biotherapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.